Stem cell shot for frailty? early safety trial begins

NCT ID NCT07462819

Not yet recruiting Symptom relief Sponsor: Ji Yan Biomedical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tests whether a stem cell product called Stemis™ is safe for older adults with mild to moderate frailty. Frailty causes weakness, slow walking, and reduced daily function, with no approved treatments. Around 12 people aged 60–85 will receive either Stemis™ or a placebo, and researchers will monitor for side effects and explore changes in strength and mobility.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Stemis™ (human umbilical cord-derived mesenchymal stem cells)
What this could lead to: If safe, this could pave the way for larger studies exploring whether stem cells can ease frailty symptoms like weakness and slow walking.
What could go wrong: This is a very early, small Phase 1 trial with only 12 people. It is designed to check safety, not effectiveness, so it may not lead to any treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FRAILTY SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Frailty

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FRAILTY SYNDROME

Contacts and locations

Locations

Taipei Medical University Hospital

Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.